Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

136.93
Delayed Data
As of Jan 13
 -0.42 / -0.31%
Today’s Change
109.12
Today|||52-Week Range
169.84
+11.92%
Year-to-Date
Drugmakers alarmed by Trump pricing threat
Jan 14 / FT.com - Paid Partner Content
Bullish and Bearish Reversals in the Market
Jan 09 / TheStreet.com - Paid Partner Content
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan 12 / Zacks.com - Paid Partner Content
Here's Why Alexion Pharmaceuticals, Inc. Stock Gave Up 36% in 2016
Jan 09 / MotleyFool.com - Paid Partner Content
Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now
Jan 11 / TheStreet.com - Paid Partner Content
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
Jan 09 / Zacks.com - Paid Partner Content
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan 11 / Zacks.com - Paid Partner Content
Company News for January 06, 2017
Jan 06 / Zacks.com - Paid Partner Content
The Monday Sights, Sounds and Biotech Buzz from the J.P. Morgan Healthcare Conference
Jan 09 / TheStreet.com - Paid Partner Content
Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
Jan 05 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close137.35
Today’s open137.03
Day’s range135.41 - 139.97
Volume1,679,672
Average volume (3 months)2,628,945
Market cap$30.7B
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)-6.94%
Earnings growth (next 5 years)+18.16%
Revenue growth (last year)+12.25%
P/E ratio83.0
Price/Sales16.57
Price/Book3.74

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.35+0.66%
BAXBaxter International...-0.06-0.13%
REGNRegeneron Pharmaceut...+3.72+1.02%
INCYIncyte Corp+0.20+0.17%
Data as of 4:00pm ET, 01/13/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)$1.25
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David Richard Brennan
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
New Haven, Connecticut

Forecasts


Search for Jobs